Ocrevus: Disability Worsening Unaffected by Relapses
A study analyzing real-world data has found that most disability worsening experienced by multiple sclerosis (MS) patients treated with Ocrevus (ocrelizumab) is not associated with relapse activity. The analysis included data from 97 patients and showed that 23.7% experienced confirmed worsening in disability, with 20 cases attributed to progression independent of relapse activity (PIRA). These findings align with clinical trials, suggesting that Ocrevus is effective in reducing disability progression in relapsing MS patients. Factors associated with PIRA risk included shorter disease duration and fewer prior MS treatments. However, the study's reliance on real-world data is a limitation.